Orexin, Hot Flashes, and Menopausal Insomnia: Early Evidence

Night sweats can wake you up, but menopause-related insomnia may involve more than a hot bedroom and an ill-timed blanket. Early human evidence suggests that orexin—a brain signaling system that promotes wakefulness and helps regulate body temperature—could contribute to both nighttime vasomotor symptoms and sleep disruption. That is a plausible unifying explanation, not a settled diagnosis.

The distinction matters because treatments often address hot flashes and insomnia as separate problems. A small randomized trial of suvorexant, an orexin receptor blocker used for insomnia, improved insomnia severity and reduced diary-rated nighttime vasomotor symptoms. Meanwhile, a much larger body of Phase 3 research shows that a separate hypothalamic pathway, KNDy/neurokinin 3 receptor signaling, can reduce hot flashes with fezolinetant. Menopause does not appear to have handed researchers one clean molecular villain. It has handed them a network.

Why hot flashes and insomnia may share a brain pathway

Vasomotor symptoms—hot flashes and night sweats—are centrally mediated. Falling estrogen appears to dysregulate hypothalamic temperature control, with overstimulation of kisspeptin, neurokinin B, and dynorphin (KNDy) neurons as the best-characterized mechanism. A 2025 systematic review by Gibson et al. also describes the frequent overlap between vasomotor symptoms and anxiety or depressive symptoms across reproductive stages in U.S. women. Sleep fragmentation, arousal, and mood symptoms often travel together, though shared symptoms do not prove one shared cause.

Orexin offers a second plausible route. Orexin signaling promotes wakefulness and participates in thermoregulation. The investigators in the suvorexant trial cited evidence that orexin increases after menopause and normalizes with estrogen therapy. Those biomarker studies were not evaluated in the trial itself, however, so this is biological rationale rather than direct proof that elevated orexin causes an individual woman's hot flashes or insomnia.

The KNDy and orexin models can both be true. KNDy/neurokinin 3 receptor signaling has the stronger clinical validation for vasomotor symptoms. Orexin may help explain why some women experience a particularly tight knot of nighttime awakenings and night sweats.

Suvorexant provides an intriguing, limited test

In a 2022 double-blind, randomized, placebo-controlled trial by Rahman et al., 56 midlife women with vasomotor symptom-associated insomnia disorder received suvorexant 10–20 mg nightly (27 participants) or placebo (29 participants) for four weeks. Suvorexant blocks orexin receptors, reducing the wake-promoting signal.

The primary endpoint was change in the Insomnia Severity Index (ISI), a patient-reported measure. ISI scores fell by 8.1 points with suvorexant (95% CI, −10.2 to −6.0) and by 5.6 points with placebo (95% CI, −7.4 to −3.9). The between-group difference was statistically significant after adjustment for baseline ISI and race (p=0.04). Participants taking suvorexant also reported significantly fewer nighttime vasomotor symptoms in diaries than placebo participants (p<0.01).

That combination is the trial's most interesting finding: one intervention improved subjective insomnia severity and nighttime hot-flash frequency. It supports the idea that orexin blockade could affect the sleep-and-night-sweat cluster. It does not establish that orexin is the primary driver of menopause symptoms, nor does it establish suvorexant as a vasomotor-symptom treatment.

Several details keep the conclusion narrow. The trial found no between-group difference in daytime vasomotor symptoms. Diary-measured wake after sleep onset and total sleep time moved in a favorable direction but did not remain significant after correction for multiple comparisons. In other words, the study demonstrated a subjective insomnia benefit and a nighttime symptom signal; it did not demonstrate an objective improvement in sleep architecture. The available report also gives the nighttime vasomotor result as a p-value, without the absolute change in episodes per night. Readers therefore cannot judge its clinical size or compare it directly with hot-flash reductions reported in fezolinetant trials.

A nighttime-only effect also leaves open a simpler explanation: better sleep maintenance may have changed how often participants woke up and registered a night sweat, rather than directly changing thermoregulatory control. Four weeks and 56 participants can generate a useful proof of concept. They cannot settle a mechanism.

Fezolinetant is the nonhormonal benchmark for hot flashes

Fezolinetant takes a different route. It blocks the neurokinin 3 receptor, targeting KNDy-related hypothalamic signaling rather than orexin. In SKYLIGHT 1, a 2023 Phase 3 randomized trial, fezolinetant 30 mg and 45 mg reduced the frequency and severity of moderate-to-severe vasomotor symptoms more than placebo. This trial, rather than the small suvorexant study, sets the evidentiary standard for nonhormonal drug treatment of hot flashes.

The result has held up across a broader program. A 2024 systematic review and meta-analysis of randomized trials found consistent efficacy and safety results for fezolinetant. A 2024 Phase 3b randomized trial also found benefit in women considered unsuitable for hormone therapy. Pooled analyses of SKYLIGHT 1 and 2 developed patient-centered thresholds for meaningful change in symptom frequency, and a 2024 subgroup analysis reported efficacy across demographic, clinical, lifestyle, and comorbidity factors.

This evidence does more than identify a treatment option. It shows that vasomotor symptoms can improve substantially through a pathway with no orexin activity. That weakens any claim that menopause-related hot flashes and insomnia are a single orexin disorder. Fezolinetant has not been validated as an insomnia treatment, however, so lowering hot-flash burden and directly treating chronic insomnia remain different clinical jobs.

Behavioral care still belongs in the plan

For insomnia, cognitive behavioral therapy for insomnia (CBT-I) remains the first-line approach. In a 2022 randomized trial of 80 menopausal women, an internet-delivered CBT program improved sleep outcomes. A 2024 systematic review of psychological therapies similarly found that most included studies reported sleep improvement with approaches such as CBT, mindfulness-based therapies, and clinical hypnosis.

These results matter because they improve sleep without requiring a claim about orexin, KNDy neurons, or any other biomarker. Behavioral treatment can reduce the insomnia burden even when hot flashes persist. It can also fit alongside medical treatment for vasomotor symptoms, although direct randomized trials of combinations such as fezolinetant plus CBT-I are not available here.

Other non-drug options have smaller evidence bases. A 2024 sham-controlled trial assigned 57 postmenopausal women to connective tissue massage or sham ultrasound three times weekly for four weeks. Massage improved physical symptoms, emotional symptoms, insomnia, and menopause-specific quality-of-life impairment versus sham. It did not measure orexin or other hypothalamic signals, so it cannot validate or refute either drug mechanism. Sage and soy isoflavones have shown modest symptom benefits in systematic reviews, but their mechanisms remain poorly characterized and their evidence is weaker than the Phase 3 fezolinetant program. The soy review reported an overall symptom effect of Hedges' g = −0.25 (95% CI, −0.42 to −0.08) across seven studies and 533 participants.

What to do with the orexin hypothesis

For frequent or severe vasomotor symptoms, fezolinetant has the most extensive nonhormonal evidence: multiple Phase 3 trials, meta-analyses, and data in people unable to use hormone therapy. It targets hot flashes directly through the better-established KNDy/neurokinin 3 receptor pathway.

For prominent sleep-maintenance insomnia with nocturnal hot flashes, suvorexant deserves a more careful conversation than a routine sleeping-pill discussion. Its one four-week trial found a statistically significant improvement in ISI scores and fewer diary-rated nighttime vasomotor symptoms. Yet it remains a single trial of 56 participants, with no statistically secure objective sleep findings after multiple-comparison correction, no daytime vasomotor benefit, no absolute nighttime hot-flash effect size in the available report, and limited safety detail for this population.

The reasonable conclusion is narrower than the headline temptation: orexin blockade may help a specific menopause symptom cluster, but it has not replaced established vasomotor-symptom care or proved a unified cause of hot flashes and insomnia.

CBT-I remains the evidence-backed starting point for insomnia, whether or not hot flashes accompany it. Treatment choices should also account for symptom timing, mood symptoms, other medications, fall risk, next-day sedation, and the individual reasons someone may prefer—or need—to avoid hormone therapy. The science supports curiosity about orexin. It does not yet support certainty.